CL2023001997A1 - Anticuerpos y péptidos de unión a antígenos para inhibidores del factor xia y sus usos - Google Patents

Anticuerpos y péptidos de unión a antígenos para inhibidores del factor xia y sus usos

Info

Publication number
CL2023001997A1
CL2023001997A1 CL2023001997A CL2023001997A CL2023001997A1 CL 2023001997 A1 CL2023001997 A1 CL 2023001997A1 CL 2023001997 A CL2023001997 A CL 2023001997A CL 2023001997 A CL2023001997 A CL 2023001997A CL 2023001997 A1 CL2023001997 A1 CL 2023001997A1
Authority
CL
Chile
Prior art keywords
antigen
inhibitors
binding peptides
fxia
present
Prior art date
Application number
CL2023001997A
Other languages
English (en)
Inventor
M Luettgen Joseph
Schneeweis Lumelle
Chao Rakestraw Ginger
Terragni Christina
Karl Dilger Andrew
Robert Pinckney Jason
Sheriff Steven
Kish Kevin
An Yongmi
R Ewing William
Richard Krystek Stanley Jr
Paul Yamniuk Aaron
Original Assignee
Bristol Myers Squibb Co
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Janssen Pharmaceutica Nv filed Critical Bristol Myers Squibb Co
Publication of CL2023001997A1 publication Critical patent/CL2023001997A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona péptidos de unión a antígenos novedosos, tales como un anticuerpo o fragmento de anticuerpo, que se unen específicamente a inhibidores selectivos de FXIa y/o inhibidores duales de FXIa y calicreína plasmática. La presente invención se refiere además a métodos para reducir el efecto antitrombótico de los inhibidores de FXIa mediante una administración a un sujeto de una dosis farmacéuticamente eficaz de los péptidos de unión a antígeno proporcionados en el presente documento. Además, la presente invención proporciona reactivos de detección y métodos para detectar el nivel de inhibidores de FXIa en una muestra biológica.
CL2023001997A 2021-01-08 2023-07-07 Anticuerpos y péptidos de unión a antígenos para inhibidores del factor xia y sus usos CL2023001997A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163135016P 2021-01-08 2021-01-08
US202163148767P 2021-02-12 2021-02-12
US202163152595P 2021-02-23 2021-02-23
US202163153045P 2021-02-24 2021-02-24

Publications (1)

Publication Number Publication Date
CL2023001997A1 true CL2023001997A1 (es) 2023-12-15

Family

ID=82322604

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001997A CL2023001997A1 (es) 2021-01-08 2023-07-07 Anticuerpos y péptidos de unión a antígenos para inhibidores del factor xia y sus usos

Country Status (13)

Country Link
US (1) US20220220220A1 (es)
EP (1) EP4274854A1 (es)
JP (1) JP2024505390A (es)
KR (1) KR20230142724A (es)
AU (1) AU2022205370A1 (es)
CA (1) CA3204552A1 (es)
CL (1) CL2023001997A1 (es)
CO (1) CO2023010266A2 (es)
IL (1) IL304210A (es)
MX (1) MX2023008142A (es)
PE (1) PE20240689A1 (es)
TW (1) TW202241964A (es)
WO (1) WO2022150624A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
BRPI0607238B8 (pt) * 2005-01-27 2021-05-25 Novimmune Sa anticorpos anti-interferon gama humano, usos dos mesmos na preparação de medicamentos e composições farmacêuticas
CN101522716B (zh) * 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN114470192A (zh) * 2015-10-13 2022-05-13 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途

Also Published As

Publication number Publication date
IL304210A (en) 2023-09-01
CA3204552A1 (en) 2022-07-14
MX2023008142A (es) 2023-09-08
CO2023010266A2 (es) 2023-09-18
KR20230142724A (ko) 2023-10-11
WO2022150624A1 (en) 2022-07-14
PE20240689A1 (es) 2024-04-10
TW202241964A (zh) 2022-11-01
US20220220220A1 (en) 2022-07-14
JP2024505390A (ja) 2024-02-06
AU2022205370A1 (en) 2023-08-24
EP4274854A1 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
ECSP17005649A (es) Anticuerpos anti-tau humanizados
UA116772C2 (uk) Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47
CL2016000324A1 (es) Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1.
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
CO2018009434A2 (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue
ECSP13012792A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
PE20170585A1 (es) Moleculas de union a antigeno biespecificas activadoras de celulas t
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
AR104280A1 (es) Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
PE20131376A1 (es) Anticuerpos para metaloproteinasa-9 de matriz
TR201904638T4 (tr) pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi.
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo